Filing Flows › LanzaTech Global (LNZA) › Q2 2026 › vs Q2 2025
LanzaTech Global (LNZA) Q2 2026 vs Q2 2025 (year over year)
LanzaTech Global's revenue fell $70K (-0.8%) from $9.1M in Q2 2025 to $9.0M in Q2 2026. The biggest changes: Engineering and other services +$1.4M (+73%); Joint development and contract research revenue −$1.0M (-44%); Biorefining revenue +$923K (+31%).
LanzaTech Global, Q2 2026: revenue $9.0M (-0.8% year over year), operating margin -109.5%, net earnings $184M, operating cash flow −$1.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Contract research | $1.0M | $1.0M | $21K | +2% |
| Joint development agreements | $275K | $1.3M | −$1.0M | -79% |
| Joint development and contract research revenue | $1.3M | $2.3M | −$1.0M | -44% |
| Biorefining revenue | $3.9M | $2.9M | $923K | +31% |
| Engineering and other services | $3.3M | $1.9M | $1.4M | +73% |
| Licensing | $595K | $1.1M | −$455K | -43% |
| Revenue | $9.0M | $9.1M | −$70K | -0.8% |
| Other income, net | $194M | −$258K | $194M | — |
| Costs & expenses | $203M | $41.6M | $162M | +389% |
| Operating costs | $18.9M | $41.3M | −$22.4M | -54% |
| Net earnings | $184M | −$32.5M | $217M | — |
| Research & development | $2.0M | $14.9M | −$13.0M | -87% |
| SG&A | $8.8M | $19.1M | −$10.4M | -54% |
| Other operating costs | $8.2M | $7.3M | $890K | +12% |
| Operating cash sources | $187M | −$7.5M | $195M | — |
| Depreciation | $962K | $1.1M | −$92K | -9% |
| Share-based compensation | $739K | $2.3M | −$1.5M | -68% |
| Cash used in operations | $1.4M | $21.7M | −$20.3M | -94% |
| Working capital & other | $187M | −$7.5M | $195M | — |
Questions
How much did LanzaTech Global's revenue grow year over year in Q2 2026?
LanzaTech Global's revenue fell $70K (-0.8%) from $9.1M in Q2 2025 to $9.0M in Q2 2026.
What drove LanzaTech Global's revenue change in Q2 2026?
Engineering and other services +$1.4M (+73%); Joint development and contract research revenue −$1.0M (-44%); Biorefining revenue +$923K (+31%).